Loading
A phase 1/2 trial of HB0036 in non-small-cell lung cancer, run by Shanghai Huaota Biopharmaceutical Co., Ltd., now recruiting.
A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05417321 by Shanghai Huaota Biopharmaceutical Co., Ltd., with 80 participants planned, started 2022-08-25 and due to reach its primary completion in 2025-08-01. Interventions recorded: HB0036.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/